$8.5 M

CBDX Mkt cap, 22-Sept-2020
Curative Biosciences Net income (Q3, 2018)-32 K
Curative Biosciences EBIT (Q3, 2018)-32 K
Curative Biosciences Cash, 31-Mar-2018982

Curative Biosciences Income Statement

Annual

USDFY, 2012FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

328.2k

Cost of goods sold

186.1k

Gross profit

142.1k

Gross profit Margin, %

43%

Sales and marketing expense

76.7k

General and administrative expense

5.6m518.4k1.7m1.6m53.2k

Operating expense total

5.7m518.4k1.7m1.6m53.2k

EBIT

(5.5m)(29.9m)3.4m(1.7m)(53.2k)

EBIT margin, %

(1683%)

Net Income

(5.5m)(29.9m)(3.4m)(1.7m)(53.2k)

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

70.4k81.7k91.8k

Cost of goods sold

28.9k30.2k111.2k

Gross profit

41.5k51.5k(19.4k)

Gross profit Margin, %

59%63%(21%)

Sales and marketing expense

15.1k21.4k15.0k

General and administrative expense

654.3k1.3m1.1m86.3k87.1k1.5m489.5k1.1m5.3k24.5k6.8k4.0k16.7k26.2k32.0k

Operating expense total

669.4k1.4m1.1m86.3k87.1k1.5m489.5k1.1m5.3k24.5k6.8k4.0k16.7k26.2k32.0k

EBIT

(627.9k)(1.3m)(1.2m)(86.3k)(87.1k)(2.9m)(505.6k)(1.1m)(5.3k)(24.5k)6.8k4.0k(16.7k)451.5k(32.0k)

EBIT margin, %

(892%)(1599%)(1262%)

Interest expense

Income tax expense

Net Income

(627.9k)(1.3m)(1.2m)(86.3k)(87.1k)(2.9m)(505.6k)(1.1m)(5.3k)(24.5k)6.8k4.0k(16.7k)451.5k(32.0k)

Curative Biosciences Balance Sheet

Annual

USDFY, 2012FY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.8k2.0k

Prepaid Expenses

19.7k1.8k

Inventories

135.5k

Current Assets

155.2k3.6k2.0k

PP&E

124.4k10.8k8.0k2.3k

Total Assets

279.6k15.7k10.0k5.1k2.3k

Accounts Payable

144.5k88.5k123.5k160.8k177.4k

Short-term debt

181.0k

Current Liabilities

458.7k249.2k705.8k620.2k633.1k

Total Debt

181.0k

Total Liabilities

705.8k620.2k633.1k

Common Stock

114.5k5.5k11.3k15.7k

Additional Paid-in Capital

8.7m47.8m50.7m52.5m52.5m

Retained Earnings

(18.1m)(51.5m)(53.2m)

Total Equity

(179.2k)(233.6k)(695.8k)(615.1k)(630.8k)

Debt to Equity Ratio

-0.8 x

Debt to Assets Ratio

11.6 x

Financial Leverage

-1.6 x-0.1 x0 x0 x0 x

Curative Biosciences Cash Flow

Annual

USDFY, 2012FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(5.5m)(29.9m)(3.4m)(1.7m)(53.2k)

Depreciation and Amortization

3.4k43.0k4.1k2.8k2.8k

Inventories

107.3k(51.0k)

Accounts Payable

37.4k79.8k37.3k16.6k

Cash From Operating Activities

(726.6k)(144.3k)(65.3k)(29.0k)(12.8k)

Purchases of PP&E

(1.7k)

Cash From Investing Activities

(1.7k)

Cash From Financing Activities

617.6k144.3k65.5k27.0k12.8k

Net Change in Cash

186.0(2.0k)

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(627.9k)(1.9m)(3.1m)(58.6k)(145.7k)(3.1m)(505.6k)(1.6m)(1.6m)(24.5k)(31.3k)(35.3k)(16.7k)(500.2k)

Depreciation and Amortization

786.01.6k2.5k2.7k3.4k1.4k2.1k712.01.4k2.1k712.01.4k1.9k

Inventories

60.1k160.4k107.0k

Accounts Payable

(2.6k)28.0k(23.8k)36.9k36.9k127.8k7.9k5.5k(1.9k)(236.0)1.1k(1.7k)(7.2k)(7.2k)

Cash From Operating Activities

(189.0k)(420.3k)(615.9k)(42.5k)(53.5k)(18.5k)(22.5k)(4.7k)(9.1k)(11.1k)(17.6k)(48.6k)(80.1k)

Purchases of PP&E

(1.7k)(1.7k)

Cash From Investing Activities

(1.7k)(1.7k)(12.5k)

Cash From Financing Activities

252.4k319.0k507.2k42.5k53.5k18.5k20.5k4.7k9.1k11.1k17.6k48.6k93.6k

Net Change in Cash

63.4k(103.0k)(110.5k)(2.0k)982.0

Interest Paid

Income Taxes Paid

Curative Biosciences Ratios

USDQ1, 2012

Financial Leverage

2.3 x